Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn:
“I look forward to presenting in a podium talk the updated results from our KOMET 007 phase 1/2 study combining the novel oral menin inhibitor ziftomenib with intensive chemotherapy 7+3 in fit patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements at the European Society of Hematology meeting ESH2026 in Stockholm.
The early results from this study have led to the ongoing registrational-intent and global randomized phase 3 study KOMET 017 of the same combination which I am honored to be the steering committee chair and where at Yale University we were the first center to open and to enroll the first patient globally.”
Stay updated with Hemostasis Today.
-
Jun 5, 2026, 20:51Atoosa Salimi: Why Aspirin and Other Antiplatelets Are Not Effective in Preventing Lacunar Ischaemic Stroke
-
Jun 5, 2026, 18:38Annie Bauzon: Clinical Significance and Causes of RBC Anisocytosis
-
Jun 5, 2026, 18:36Nandan Lad: Microclots as the Cause of Secondary Stroke After Subarachnoid Hemorrhage
-
Jun 5, 2026, 18:32George Sands: A Thoughtful Editorial on Low-Dose Rivaroxaban in Advanced CKD
-
Jun 5, 2026, 18:29Zain Khalpey: Recognizing High-Risk Coronary Hematoma Characteristics During PCI
-
Jun 5, 2026, 18:28Mirza Imail Baig: Silent but Significant – The Clinical Importance of Pulmonary Embolism
-
Jun 5, 2026, 17:26Anzila Waseem: Diet and Warfarin – A Guide to INR Stability
-
Jun 5, 2026, 17:06Lukas Mayer-Suess: How to Best Care for Patients Suffering Stroke Due to Isolated Cervical Internal Carotid Artery Occlusion
-
Jun 5, 2026, 17:02Sudhir Kumar: How Iron Deficiency Anemia Falsely Raises Diabetes Lab Results